RALA/mGPC2 mRNA vaccine delays neuroblastoma growth 10-11 days, reducing tumor volume 70% in mice.

Neuroblastoma is an aggressive pediatric solid tumor, accounting for 15% of cancer-related deaths in children. Despite its severity, there remains a significant gap in the anticancer vaccine development pipeline, with no published experimental or clinical trial data on mRNA vaccines for this disease. This study addresses this unmet need by targeting glypican 2 (GPC2), a potent tumor-associated antigen highly expressed in neuroblastoma and other cancer subtypes, presenting a promising target for immunotherapy.

Researchers developed the first mRNA vaccine for neuroblastoma, utilizing the self-assembling peptide RALA for delivering mRNA encoding murine GPC2 (mGPC2). They performed rigorous in vitro characterization of the vaccine nanoparticle formulations, assessing cellular uptake and functionality. For in vivo studies, mice were immunized with RALA/mGPC2 in a subcutaneous murine model of MYCN-amplified neuroblastoma. The primary endpoints included evaluating antigen-specific cellular immune responses (e.g., IFN-γ, IL-2, TNF-α expression) and assessing tumor development and volume compared to unvaccinated control groups.

Immunization with the RALA/mGPC2 vaccine successfully generated a robust antigen-specific cellular immune response against GPC2. This response was characterized by significant increases in IFN-γ and IL-2 expression by splenocytes, alongside elevated TNF-α expression by both CD4+ and CD8+ T cells, indicating a strong T-cell mediated immunity.

The therapeutic efficacy was striking: immunization delayed tumor development by 10-11 days and reduced tumor volume by a substantial 70% compared with unvaccinated controls in the subcutaneous neuroblastoma model. These findings demonstrate the vaccine's ability to not only elicit a potent immune response but also translate it into significant anti-tumor effects in vivo.